METHODS: This case report details the application of SRS for recurrent skull base AcCCs. A 71-year-old male with a history of resection for a right mandibular AcCC 23 years earlier experienced tumor recurrence involving the right cavernous sinus and nasal cavity. He underwent endoscopic transnasal surgery followed by SRS targeting different tumor locations-the cavernous sinus to the pterygopalatine fossa, maxillary sinus, and clivus-each with a prescribed dose of 20 Gy to the 40% to 50% isodose line. After the first skull base metastasis, additional sessions of localized SRS after endoscopic surgery led to a 12-year survival without sequela.
CONCLUSIONS: This is a report indicating that SRS for skull base AcCCs can achieve favorable local control, functional preservation, and long-term survival. SRS may be suitable for skull base AcCC given the lesion\'s tendency toward multiple local recurrences. Further investigation is needed to validate the treatment\'s efficacy.
方法:本病例报告详细介绍了SRS在复发性颅底AcCC中的应用。一名71岁的男性,有23年前的右下颌AcCC切除史,经历了涉及右海绵窦和鼻腔的肿瘤复发。他接受了鼻内镜手术,然后是针对不同肿瘤位置的SRS-海绵窦至翼腭窝,上颌窦,和clivus-各自的处方剂量为20Gy至40%至50%的等剂量线。在第一次颅底转移后,内镜手术后再进行局部SRS治疗,可获得12年无后遗症的生存期.
结论:这是一份报告,表明颅底AcCC的SRS可以实现良好的局部控制,功能保存,和长期生存。考虑到病变倾向于多次局部复发,SRS可能适用于颅底AcCC。需要进一步的研究来验证治疗的疗效。